ABSTRACT Ganoderma lucidum is a medicinal mushroom known for its wide range of biological activities, making it one of the safest and most effective therapeutic mushrooms. It contains numerous biologically active compounds. The present study aimed to isolate, purify, and identify biologically active inhibitors from G. lucidum and evaluate their various biological potential, along with validation through computational analysis. An ethanolic extract of G. lucidum was subjected to column chromatography. Solvents of increasing polarity, including n‐hexane, chloroform, ethyl acetate, and n‐butanol, were employed to obtain different fractions. These fractions were analyzed for phytochemical constituents, and functional groups were characterized using Fourier Transform Infrared Spectroscopy (FT‐IR). Bioactive metabolites were further identified using Liquid Chromatography‐Mass Spectrometry (LC‐MS). The LC‐MS analysis revealed the presence of numerous compounds, representing the diverse classes. Enzyme inhibition assays demonstrated strong antidiabetic activity, with fraction O showing the highest α‐glucosidase inhibition (95 ± 0.16%) and α‐amylase inhibition (90 ± 0.78%) at 6 mg/ml, while fraction G exhibited moderate inhibition. In silico molecular docking analysis identified four major binding sites, with Ganodermadiol showing the highest binding affinity (‐8.1 kcal/mol) toward the PPARG (ID: 8B8X) receptor, suggesting its strong potential as a therapeutic candidate for Type 2 diabetes mellitus.
Afzal et al. (Mon,) studied this question.